Combination of human tumor necrosis factor-alpha (hTNF-α) gene delivery with gemcitabine is effective in models of pancreatic cancer

Cancer Gene Therapy

Volumn 16, Issue 11, 2009, Pages 841-847

  Murugesan, S R ^a   King, C R ^a   Osborn, R ^a   Fairweather, W R ^b   O'Reilly, E M ^c   Thornton, M O ^a   Wei, L L ^a  

^a GENVEC INC   (United States)

^b Flower Valley Consulting Inc   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adenovirus vector; Gene therapy; Human pancreatic cancer; Tumor necrosis factor

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; GEMCITABINE; TNFERADE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 70350090156     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.32     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
3. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 2006; 5: 1387-1395.
4. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, Bonora A et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcita-bine. Biochim Biophys Acta 2007; 1773: 1095-1106.
5. Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005; 16: 35-53.
6. MacGill RS, Davis TA, Macko J, Mauceri HJ, Weichsel-baum RR, King CR. Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response. Clin Exp Metastasis 2007; 24: 521-531.
7. Mauceri HJ, Beckett MA, Liang H, Sutton HG, Pitroda S, Galka E et al. Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther 2009; 16: 373-381.
8. Lejeune FJ, Lienard D, Matter M, Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006; 6: 6.
9. Marr RA, Hitt M, Muller WJ, Gauldie J, Graham FL. Tumour therapy in mice using adenovirus vectors expressing human TNFa. Int J Oncol 1998; 12: 509-515.
10. Rasmussen H, Rasmussen C, Lempicki M, Durham R, Brough D, King CR et al. TNFerade biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 2002; 9: 951-957.
11. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004; 22: 592-601.
12. Posner M, Chang KJ, Rosemurgy A, Stephenson J, Khan M, Reid T et al. Multi-center, phase 2/3, randomized, controlled clinical trial using TNFerade gene delivery combined with chemoradiation in patients with locally advanced pancreatic cancer (LPAC). Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2007.
13. Lopez CA, Kimchi ET, Mauceri HJ, Park JO, Mehta N, Murphy KT et al. Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther 2004; 3: 1167-1175.
14. Park JO, Lopez CA, Gupta VK, Brown CK, Mauceri HJ, Darga TE et al. Transcriptional control of viral gene therapy by cisplatin. J Clin Invest 2002; 110: 403-410.
15. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996; 70: 6497-6501.
16. Kazuno H, Sakamoto K, Fujioka A, Fukushima M, Matsuda A, Sasaki T. Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl) cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line. Cancer Sci 2005; 96: 295-302.
17. Manome Y, Kunieda T, Wen PY, Koga T, Kufe DW, Ohno T. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther 1998; 9: 1409-1417.
18. Gupta VK, Park JO, Jaskowiak NT, Mauceri HJ, Seetharam S, Weichselbaum RR et al. Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol 2002; 9: 500-504.
19. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786-791.
20. Staba MJ, Mauceri HJ, Kufe DW, Hallahan DE, Weichsel-baum RR. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 1998; 5: 293-300.
21. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 1992; 10: 406-413.
22. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-498.
23. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 20,20-difluorodeoxycytidine 50-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991; 27: 258-262.
24. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988; 80: 751-755.
25. Pober JS, Min W. Endothelial cell dysfunction, injury and death. Handb Exp Pharmacol 2006; 176(Pt 2): 135-156.